Clinical trial NCT01088373: Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q
Official title: A Phase II Study of the Efficacy and Safety of Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Myelodysplastic Syndromes
Lead sponsor: Groupe Francophone des Myelodysplasies
Sponsor class: OTHER
Collaborators: name: Celgene
First posted: 2010-03-17
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Higher risk MDS with del(5q) carry very poor prognosis, but show some response to azacitidine and Lenalidomide as single agents . The combination of Lenalidomide and Azacytidine is currently tested in non del 5q MDS patients. Preliminary results have been recently presented at ASH meeting (Sekeres et al, 2007).

Overall, the combination of Lenalidomide and Azacitidine is well-tolerated and early results suggest some efficacy in advanced MDS without del 5q.

In this trial, we will combine Lenalidomide to Azacytidine in higher risk MDS with del (5q).

Patients will receive azacitidine( 75mg/m2/day for 5 days every 28 days) combined to escalating doses of lenalidomide (starting at relatively low dose).

For patients in hematological CR, PR, HI or marrow CR after cycle 2 or 4, it is mandatory to continue on Azacitidine + Lenalidomide as long as there is no unacceptable toxicity or overt progression, with the schedule that yielded response.

In patient still responding after 52 weeks, the drug will continue to be supplied, and follow up until death will be continued in all patients.


Eligibility criteria: Inclusion Criteria:

1. age \> ou = 18 years and \< 75 years.
2. must understand and voluntarily sign an informed consent form.
3. patient considered ineligible for intensive chemotherapy due to age, cardiac contraindication to anthracyclines, comorbidities, previous failure of intensive chemotherapy, or patient willing to avoid intensive chemotherapy.
4. must be able to adhere to the study visit schedule and other protocol requirements.
5. prior thalidomide allowed.
6. documented diagnosis of MDS (according to FAB definition, ie. with marrow blasts up to 30%, or CMML with WBC \< 13000/mm3 that meets IPSS criteria for intermediate-2 or high-risk disease.
7. with an associated del 5q\[31\](the deleted chromosomal region must include 5q\[31\]), with or without additional cytogenetic abnormalities.
8. female subjects of childbearing potential must:

   * understand the study drug is expected to have a teratogenic risk.
   * agree to have a medically supervised pregnancy test with a minimum sensitivity of 25mIU/ml on the day of the study visit or in the 3 days prior to the study visit once the subject has been on effective contraception for at least weeks. This requirement also applies to women of childbearing potential who practice complete and continued abstinence. the test should ensure the subject is not pregnant when she starts treatment.
   * agree to have a medically supervised pregnancy test every 4 weeks including 4 weeks after the end of study treatment, except in the case of confirmed tubal sterilization. these pregnancy tests should be performed on the day of the study visit or in the 3 days prior to the study visit.

   this requirement also applies to women of childbearing potential who practice complete and continued abstinence.

   \* agree to use, and to be able to comply with effective contraception without interruption, 4 weeks before starting study drug throughout the entire duration study drug therapy(including doses interruptions)and for 3 months after the end of the study drug therapy even if she has amenorrhea this applies unless the subject commits to absolute and continuous abstinence confirmed on a monthly basis, to avoid pregnancy for the duration of study.

   the following are effective methods of contraception:
   * implant
   * levonorgestrel-releasing intrauterine system(IUS)
   * Medroxyprogesterone acetate depot, tubal sterilization.
   * sexual intercourse with a vasectomised male partner only(vasectomised must be confirmed by two negative semen analyses), ovulation inhibitory progesterone-only pills(i.e.desogestrel).

   if not established on effective contraception, the female subject must be referred to an appropriately trained health care professional for contraceptive advice in order that contraception can be initiated.

   Because of the increased risk of venous thromboembolism in patients with multiple myeloma taking lenalidomide and dexamethasone, combined oral contraceptive pills are not recommended. If a female subject is currently using combined oral contraception, the patient should switch to one of the effective methods listed above. The risk of venous thromboembolism continues for 4 to 6 weeks after discontinuing combined oral contraception. The efficacy of contraceptive steroids may be reduced during co-treatment with dexamethasone.

   Implants and levonorgestrel-releasing intrauterine systems are associated with an increased risk of infection at the time of insertion and irregular vaginal bleeding. Prophylactic antibiotics should be considered particularly in patients with neutropenia .

   Copper-releasing intrauterine devices are generally not recommended due to the potential risks of infection at the time of insertion and menstrual blood loss which may compromise patients with neutropenia or thrombocytopenia.
   * Understand that even if she has amenorrhea, she must follow all the advice on effective contraception.
   * She understands the potential consequences of pregnancy and the need to rapidly consult if there is a risk of pregnancy
9. Male patients must :

   * Agree the need for the use of a condom if engaged in sexual activity with a woman of childbearing potential. during the entire period of treatment, even if disruption of treatment and during 3 months after end of treatment
   * Agree not to conceive during treatment and study drug therapy (including doses interruptions) and for 3 months after the end of the study drug therapy
   * Agree not to donate semen during study drug therapy and for one week after end of study drug therapy.
   * Agree to learn about the procedures for preservation of sperm., before starting treatment
10. All subjects must :

    * Agree to abstain from donating blood while taking study drug therapy and for one week following discontinuation of study drug therapy.
    * Agree not to share study medication with another person and to return all unused study drug to the investigator.
11. Signed informed consent prior to start of any study-specific procedures,
12. Ability to participate to a clinical trial and adhere to study procedures.

    * Criteria for women of non-childbearing potential :

A female patient or a female partner of a male patient is considered to have childbearing potential unless she meets at least one of the following criteria:

* Age ≥ 50 years and naturally amenorrhoeic for ≥ 1 year (amenorrhoea following cancer therapy does not rule out childbearing potential)
* Premature ovarian failure confirmed by a specialist gynaecologist
* Previous bilateral salpingo-oophorectomy, or hysterectomy
* XY genotype, Turner syndrome, uterine agenesis.

Primary outcomes:
measure: To identify the "safe most successful dose"(sMSD) that is the dose level where the probabilities of success is maximized across the dose levels and the toxicity rate is kept within acceptable boundaries.
timeFrame: 2 and 4 months of treatment
Secondary outcomes:
measure: response rate and safety
timeFrame: 36 months
Other outcomes:
Locations:
city: Le Kremlin-Bicêtre
country: France
facility: Hôpital kremlin Bicêtre
state: IDF
city: Nancy
country: France
facility: Chu Brabois
state: Vandoeuvre
city: Amiens
country: France
facility: CHU d'Amiens
city: Angers
country: France
facility: CHU Angers
city: Bayonne
country: France
facility: Hôpital de la cote basque
city: Bobigny
country: France
facility: Hôpital Avicenne
city: Bordeaux
country: France
facility: CHU Haut-Lévèque
city: Cergy-pontoise
country: France
facility: CH René Dubos
city: Clermont Ferrand
country: France
facility: CHU de
city: Corbeil-Essonnes
country: France
facility: Centre Hospitalier Sud-Francilien
city: Creteil
country: France
facility: CHU Henri Mondor
city: Grenoble
country: France
facility: CHU de Grenoble
city: Le mans
country: France
facility: CH Le mans
city: Lens
country: France
facility: Centre Hospitalier de Lens
city: Limoges
country: France
facility: CHRU de Limoges
city: Lyon
country: France
facility: Hôpital Edouard Heriot, dpt Hématologie Clinique
city: Marseille
country: France
facility: Institut Paoli-Calmette, Département d'hématologie
city: Meaux
country: France
facility: Centre Hospitalier de Meaux
city: Nantes
country: France
facility: Hopital de l'Hotel Dieu, Hematology Dpt
city: Nice
country: France
facility: CHU Archet
city: Orléans
country: France
facility: CHR La Source orléans
city: Paris
country: France
facility: Hôpital Saint Louis
city: Paris
country: France
facility: Saint-Louis Hospital
city: Paris
country: France
facility: Hôpital Saint-Antoine
city: Paris
country: France
facility: Hôpital la pitié-Salpétrière
city: Paris
country: France
facility: Hopital Cochin Service d'Hématologie
city: Perpignan
country: France
facility: Hôpital Maréchal Joffre
city: Poitiers
country: France
facility: Hôpital Jean-Bernard
city: Rodez
country: France
facility: centre hospitalier Jacques Puel
city: Rouen
country: France
facility: Hôpital Henri Becquerel
city: Toulouse
country: France
facility: Hôpital Purpan, médecine Interne
city: Toulouse
country: France
facility: Hôpital PURPAN, Service d'Hématologie Clinique
city: Tours
country: France
facility: CHU Bretonneau
city: Villejuif
country: France
facility: Institut gustave Roussy
Study officials:
affiliation: GFM
name: Lionel ADES, MD
role: PRINCIPAL_INVESTIGATOR
References: